For
immediate
release
1 May 2024
CVS Group
plc
("CVS" or the
"Company" and, together with its subsidiaries, the
"Group")
Appointment of Non-executive
Chair
CVS, the UK listed veterinary group
and a leading provider of veterinary services, announces the
appointment of David Wilton as Chair with effect from 1 May
2024.
David has served as an Independent
Non-executive Director of the Company since September
2021.
David is a qualified Chartered
Accountant with more than 30 years' post-qualification experience
as a Chief Financial Officer, Non-Executive Director (NED), Chair
and consultant after many years in corporate finance, primarily in
mid-cap M&A with Rothschilds. David has held roles in both
public and private-equity backed companies including as CFO of Sumo
Group plc, Group Finance Director of WYG plc and NED and Chair of
the Audit Committee of Sweett Group plc. David was NED and
subsequently Chair at Frontier Developments plc until November
2023. David is currently also NED and Chair Designate at Gateley
(Holdings) plc. He has extensive experience of people businesses
and of regulatory processes. David also brings to the Chair role a
significant amount of technical expertise, which will support CVS
in its strategic delivery of investment in technology.
David Wilton's appointment follows a
comprehensive search by the Nomination Committee, supported by a
blue chip recruitment firm who sourced a number of high quality
candidates.
The Board would like to thank
Deborah Kemp, the Group's Senior Independent Director who has been
acting as Interim Chair during the search period.
The Board is committed to high
standards of corporate governance and will commence a search for a
new Independent Audit Committee Chair. David will remain as Audit
Committee Chair until this process is completed, at which point he
will then step down as a member of the Audit Committee.
David Wilton, Non-executive Chair,
commented: "I am delighted to take on the role of Chair. I know the
business well and I look forward to supporting the executive
management team even more closely as we continue to grow the
business and deliver value for all of our
stakeholders."
Richard Fairman, CEO, commented: "On
behalf of the Board and colleagues at CVS, I would like to
congratulate David on his appointment as Chair, and thank Deborah
for her contribution during her position as Interim
Chair."
CVS
Group
plc
via
Camarco
Richard Fairman, CEO
Scott Morrison, Company
Secretary
Peel Hunt LLP (Nominated Adviser & Joint
Broker)
+44 (0)20 7418
8900
Christopher Golden / James Steel /
Andrew Clark / Lalit Bose
Berenberg (Joint Broker)
+44 (0)20 3207
7800
Toby Flaux / Ben Wright / James
Thompson / Milo Bonser
Camarco (Financial
PR)
Ginny Pulbrook
+44 (0)7961 315 138
Geoffrey Pelham-Lane
+44 (0)7733 124 226
About CVS Group plc
(www.cvsukltd.co.uk)
CVS Group is an AIM-listed
provider of veterinary services with operations in the UK,
Australia, the Netherlands and the Republic of Ireland. CVS
is focused on providing high-quality clinical services to its
clients and their animals, with outstanding and dedicated clinical
teams and support colleagues at the core of its
strategy.
The Group operates c.500 veterinary
practices across its four territories, including specialist
referral hospitals and dedicated out-of-hours sites. Alongside the
core Veterinary Practices division, CVS operates Laboratories
(providing diagnostic services to CVS and third-parties),
Crematoria (providing pet cremation and clinical waste disposal for
CVS and third-party practices) and the Group's online retail
business ("Animed Direct").
The Group employs c.9,100 personnel,
including c.2,400 veterinary surgeons and c.3,400
nurses.